Table 2.
Activity/assessment | Study period | |||||
−1 | 0 | T1 | T2 | T3 | ||
Prestudy screening/consent (day −1) |
Prestudy baseline/randomisation (day 0) |
Study visit 1 (day 3) |
Study visit 2 (day 7) |
Study visit 3 (day 14) |
||
Enrolment | Eligibility screen | X | ||||
Informed consent | X | |||||
Randomisation | X | |||||
Characteristic | X | |||||
Intervention | Mupirocin plus aFGF | ☆————————————☆ | ||||
Mupirocin plus placebo | ★————————————★ | |||||
Assessment | VAS for measuring nipple pain | X | X | X | X | |
NTS | X | X | X | X | ||
MAPP-QOL | X | X | X | X | ||
Time to complete nipple pain relief | X | X | X | |||
Time to complete healing of nipple trauma | X | X | X | |||
Outcomes associated with the infant feeding | X | X | X | |||
Adverse events | X | X | X |
☆Experimental group; ★ Control group.
aFGF, acidic fibroblast growth factor; MAPP-QOL, Maternal Postpartum Quality Of Life; NTS, Nipple Trauma Score; VAS, Visual Analogue Scale